Consistently, a marginally significant decrease in proliferating (Ki‐67 + ) ADC cancer cells was found at the end of the observation period in tumors bearing siTIMP‐1 ADC‐TAFs as compared to controls (Figure 6B ).
← all excerpts
Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma.
1
—
—